BioCentury | Sep 20, 2018
Distillery Therapeutics

Cancer

...compound in animal models of Gα-q-mutant uveal melanoma. TARGET/MARKER/PATHWAY: G protein q polypeptide (Gα-q; GNAQ); regulator of G-protein signaling 2 (RGS2)...
...above email: kblumer@wustl.edu Claire Quang Washington University School of Medicine in St. Louis G protein q polypeptide (G-ALPHA-q) (GNAQ) Regulator of G-protein signaling 2 (RGS2) Melanoma...
BioCentury | Mar 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: February 2018

New Therapeutic Targets and Biomarkers: February 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during February 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Feb 14, 2018
Distillery Therapeutics

Neurology

INDICATION: Addiction Mouse studies suggest inhibiting RGS20 could help treat morphine addiction. In periaqueductal gray samples from morphine-treated mice, levels of RGS20 protein were higher than in samples from vehicle-treated mice. In mice treated with...
BioCentury | Nov 2, 2016
Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling; tissue markers Single-cell transcriptomic profiling of α, β, γ and δ pancreatic islet cells could help predict the risk of Type II diabetes. In four patients with Type II diabetes and six...
BioCentury | May 23, 2013
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Depression; pain Regulator of G-protein signaling 4 (RGS4) Mouse studies suggest modulating RGS4 activity could help enhance the efficacy of antidepressant drugs. In mice, viral...
BioCentury | Mar 14, 2013
Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Hypertrophy Endothelial cell nitric oxide synthase 3 (NOS3; eNOS); regulator of G-protein signaling 4 (RGS4) In vitro and mouse studies suggest inhibiting eNOS or...
BioCentury | Mar 8, 2012
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Seizures Protein phosphatase 1 regulatory inhibitor subunit 9A (PPP1R9A; neurabin-1); regulator of G-protein signaling 4 (RGS4) Mouse studies suggest inhibiting PPP1R9A or RGS4 could help...
BioCentury | Mar 8, 2012
Distillery Therapeutics

Indication: Autoimmune Disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease Indoleamine 2, 3-dioxygenase (INDO; IDO) Mouse studies suggest IDO could help treat and prevent autoimmune diseases. In lupus-prone mice, an IDO inhibitor...
BioCentury | Feb 9, 2012
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) Regulator of G-protein signaling 4 (RGS4) Mouse studies suggest inhibiting RGS4 could help treat PD. In a mouse model of PD, Rgs4...
BioCentury | Aug 5, 2010
Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Heart failure Regulator of G-protein signaling 5 (RGS5); MAP kinase kinase 1 (MAP2K1; MEK1); MAP kinase 3 (MAPK3; ERK-1); MAPK1 (ERK-2) Mouse studies suggest...
Items per page:
1 - 10 of 14